Concepedia

Author

M. C. Genovese

Stanford University

Also Known As

E. Guarin, Genovese, M., J. Ledingham, K. Qi, M C Genovese, M Genovese, M. C. Genovese, M. Genovese, M. genovese, M.C. Genovese

64

Publications

1.1K

Citations

10

H-Index

8

Concepts

All Affiliations

Stanford UniversityEli Lilly (United States)Medical University of ViennaPalo Alto UniversityMetroplex Clinical Research Center
MC

About

M. C. Genovese is an author at Stanford University specializing in medicine, rheumatology, and clinical trials.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

42

2

Pathology

1

1

27

3

Pharmacology

1

1

15

4

Rheumatology

1

1

15

5

Clinical Trials

1

1

15

M. C. Genovese

×

10

Publications

932

Citations

10

H-Index

YearCitations

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

Graeme Jones, Anthony Sebba, Jianhui Gu,

Annals of the Rheumatic Diseases

2009

789

Lemierreʼs Syndrome

Fred A. Lopez, M. C. Genovese, J. Loutit

Southern Medical Journal

1997

27

OP0029 Baricitinib, An Oral Janus Kinase (JAK)1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to TNF Inhibitors: Results of the Phase 3 RA-Beacon Study

M. C. Genovese, Joel M. Kremer, Omid Zamani,

Annals of the Rheumatic Diseases

2015

26

24-Week Results of a Blinded Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Januse Kinase 2 Inhibitor, in Combination with Traditional Disease Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis.

M. C. Genovese, Ed Keystone, P. W. J. Taylor,

Oxford University Research Archive (ORA) (University of Oxford)

2012

15

OP0121 Enbrel® (etanercept) vs. methotrexate (mtx) in early rheumatoid arthritis (era trial): two-year follow-up

M. C. Genovese, RW Martin, Roy Fleischmann,

Annals of the Rheumatic Diseases

2001

15

SAT0117 Sarilumab, a Subcutaneously-Administered, Fully-Human Monoclonal Antibody Inhibitor of The IL-6 Receptor: Relationship Between Eular Responses and Change from Baseline of Selected Clinical Parameters

M. C. Genovese, R Fleischmann, Stefano Fiore,

Annals of the Rheumatic Diseases

2013

14

OP0201 A phase 3 study of the efficacy and safety of ixekizumab in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitor(s)

Peter Nash, Bruce Kirkham, Masato Okada,

Annals of the Rheumatic Diseases

2017

14

FRI0123 SAFETY PROFILE OF BARICITINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS UP TO 8.4 YEARS: AN UPDATED INTEGRATED SAFETY ANALYSIS

M. C. Genovese, Josef S Smolen, Tsutomu Takeuchi,

Annals of the Rheumatic Diseases

2020

12

A7.16 Characterisation of changes in lymphocyte subsets in baricitinib-treated patients with rheumatoid arthritis in two phase 3 studies

Paul Emery, Iain B. McInnes, M. C. Genovese,

Annals of the Rheumatic Diseases

2016

10

SAT0151 EFFICACY AND SAFETY OF UPADACITINIB VERSUS ABATACEPT IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (SELECT-CHOICE): A DOUBLE-BLIND, RANDOMIZED CONTROLLED PHASE 3 TRIAL

Andrea Rubbert‐Roth, Jeffrey Enejosa, Aileen L. Pangan,

Annals of the Rheumatic Diseases

2020

10

Page 1